Trial reportDrugs1991
Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.
Trial report in Drugs, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 6 syntheses or guidelines pooled it, 105 citations in OpenAlex.
- Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children.The Cochrane database of systematic reviews · 2010Pooled it
- Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma.The Cochrane database of systematic reviews · 2010Pooled it
- Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children.The Cochrane database of systematic reviews · 2009Pooled it
- Pooled it
- Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma.The Cochrane database of systematic reviews · 2007Pooled it
- Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2006Pooled it
- New combinations in the treatment of COPD: rationale for aclidinium-formoterol.Therapeutics and clinical risk management · 2016Review
- Role of arformoterol in the management of COPD.International journal of chronic obstructive pulmonary disease · 2008Review
- Short-term safety and tolerability of double-dose salmeterol/fluticasone propionate in adult asthmatic patients.Clinical drug investigation · 2005Article
- Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease.Drugs · 2004Review
- Clinical pharmacokinetics of salmeterol.Clinical pharmacokinetics · 2002Review
- Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.Drugs & aging · 2001Review
- Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthma.PharmacoEconomics · 2000Review
- Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma.Drugs · 2000Review
- Salmeterol/fluticasone propionate combination.Drugs · 1999Review
- Obstructive Sleep Apnea and Hypopnea Efficacy and Safety of a Long-Acting beta2-Agonist.Sleep & breathing = Schlaf & Atmung · 1999Article
- Review
- Long-acting beta 2-agonists. Role in primary care asthma treatment.Canadian family physician Medecin de famille canadien · 1997Review
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Salmeterol xinafoate, like salbutamol (albuterol), is a saligenin derivative, and a selective beta 2-adrenoceptor agonist. It produces bronchodilation for at least 12 hours following inhalation of a single 50 micrograms dose. Salmeterol is intended for regular twice-daily treatment of reversible airways obstruction and not for immediate symptomatic relief, and when used in this manner, 50 micrograms twice daily is more effective than salbutamol 200 micrograms or terbutaline 500 micrograms administered 4 times daily, or individually titrated oral doses of theophylline in improving objective and subjective criteria of efficacy in patients with mild to moderate asthma. Salmeterol 100 micrograms inhaled twice daily may provide better control than the lower dose in patients with severe asthma. The long duration of effect of salmeterol makes it particularly suitable for treating patients with nocturnal asthma in whom it improves sleep quality. The place of salmeterol, like that of other beta 2-adrenoceptor agonists used regularly in the treatment of asthma, is being debated. Patients in need of regular beta 2-agonist therapy should also be regarded as candidates for inhaled corticosteroids to counteract underlying inflammation. Thus, salmeterol may be particularly useful in patients requiring regular treatment with beta 2-agonists for nocturnal asthma and results of trials in progress involving large numbers of patients are awaited with interest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.